Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook ...

The price target boosts come after LLY stock rose 30% during November amid a strong rally in the shares. The bull run comes ...

Eli Lilly’s stock has recently seen its consensus analyst price target rise from $1,003 to $1,024. This change reflects ...

Surging stock prices and earnings growth potential make Meta Platforms, ASML, and Eli Lilly ripe for stock splits in the new ...

Eli Lilly (NYSE: LLY) has outperformed the market over the past 5 years by 35.44% on an annualized basis producing an average annual return of 48.41%. Currently, Eli Lilly has a market capitalization ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

J. L. Bainbridge & Co. bought 61,258 shares of Eli Lilly and Company for an estimated $45.6 million in the third quarter. Post-transaction, the wealth advisory reported owning 61,782 shares of Eli ...

French biotech company Abivax's shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly could ...

Discover why Eli Lilly and Company's retatrutide weight loss breakthrough positions LLY as a leader in obesity therapeutics.